IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37(TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-443) (MUS MUSCULUS VH (IGHV1S135*01 (96.90%)-(IGHD)-IGHJ4*01) (8.8.12) (1-119)-IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W (194) (120-216), HINGE (217-229), CH2 (230-336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443)) (120-443)), (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV6-25*01 (93.70%)-IGKJ4*01) (6.3.9) (1'-107')-IGKC*01 (108'-214')); DIMER (223-223'':226-226'':228-228'')-TRISDISULFIDE
Follicular Lymphoma
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 65/ 100
Competitive context
210 Active assets in the Follicular Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Romidepsin City of Hope Medical Center | Phase 2 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37(TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN (1-443) (MUS MUSCULUS VH (IGHV1S135*01 (96.90%)-(IGHD)-IGHJ4*01) (8.8.12) (1-119)-IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W (194) (120-216), HINGE (217-229), CH2 (230-336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443)) (120-443)), (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV6-25*01 (93.70%)-IGKJ4*01) (6.3.9) (1'-107')-IGKC*01 (108'-214')); DIMER (223-223'':226-226'':228-228'')-TRISDISULFIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →